Infarmed, the Portuguese Medicines and Health Products Authority, has authorized the use of the medicine pembrolizumab for the treatment of metastatic triple negative breast cancer, metastatic colorectal cancer, persistent cervical cancer, metastatic oesophageal cancer, renal cell carcinoma in adults and some cases of melanoma. Read more here: https://bit.ly/3OpAWAy
ELS can and will help you develop your new medicine, carry out feasibility studies and get your product regulated. If you would like to know more, contact your local advisor via this link: https://www.els-solutions.com/onde-estamos/ or by email: info@elssolutions.pt
